• Explore /
  • Poster
  • / Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.

Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study.

Abstract Poster

Authors

null

Keun Wook Lee

Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea

Keun Wook Lee , Li-Yuan Bai , Minkyu Jung , Jieer Ying , Young Hyuck Im , Do-Youn Oh , Jae Yong Cho , Sang Cheul Oh , Yee Chao , Huiyan Li , Ping Zhou , Yuanyuan Bao , Yoon-Koo Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT04276493

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4032)

DOI

10.1200/JCO.2022.40.16_suppl.4032

Abstract #

4032

Poster Bd #

20

Abstract Disclosures

Similar Posters

First Author: Keun Wook Lee

First Author: Do-Youn Oh

First Author: Yu-Xian Bai

First Author: Josep Tabernero